Presentation: Viera BioScience will present at the 2017 Academy of Regenerative Practices Conference on February 25th. The talk will cover preclinical and clinical data of AngioMune, a cord blood derived product.
Product: AngioMune is a “universal donor” T regulatory cell product that can stimulate angiogenesis, or new blood vessel formation. It has potential applications for treating peripheral artery disease and coronary artery disease.
Market: The market size for angiogenesis stimulating products is in the billions of dollars annually in the U.S. Viera BioScience aims to impact many patients who have no treatment options.